Salarius Pharmaceuticals Files 8-K: Material Agreement & Security Holder Changes
Ticker: DCOY · Form: 8-K · Filed: Jul 21, 2025 · CIK: 1615219
Sentiment: neutral
Topics: material-agreement, security-holder-rights, corporate-filing
Related Tickers: SLRX
TL;DR
Salarius Pharma (SLRX) filed an 8-K on 7/18, reporting a material agreement and changes affecting security holders.
AI Summary
On July 18, 2025, Salarius Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The filing also indicates modifications to the rights of security holders and includes financial statements and exhibits. The company, formerly known as Flex Pharma, Inc., is based in Houston, TX.
Why It Matters
This 8-K filing signals significant corporate activity for Salarius Pharmaceuticals, potentially impacting its financial structure and the rights of its investors.
Risk Assessment
Risk Level: medium — Material definitive agreements and modifications to security holder rights can introduce significant changes and potential risks for investors.
Key Numbers
- 001-36812 — SEC File Number (Identifies the company's filing history with the SEC.)
- 46-5087339 — IRS Employer Identification Number (Unique identifier for tax purposes.)
Key Players & Entities
- Salarius Pharmaceuticals, Inc. (company) — Registrant
- July 18, 2025 (date) — Date of earliest event reported
- Flex Pharma, Inc. (company) — Former company name
- 2450 Holcombe Blvd. Suite X Houston, TX 77021 (address) — Principal executive offices
- 713-913-5608 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the Material Definitive Agreement entered into by Salarius Pharmaceuticals?
The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on July 18, 2025.
What specific modifications were made to the rights of security holders?
The filing indicates 'Material Modifications to Rights of Security Holders' as an item information, but the specific details of these modifications are not provided in the provided text.
When was Salarius Pharmaceuticals, Inc. formerly known as Flex Pharma, Inc.?
The date of the name change from Flex Pharma, Inc. to Salarius Pharmaceuticals, Inc. is not explicitly stated in the provided text, only that it is the former name.
What is the primary business of Salarius Pharmaceuticals, Inc.?
Salarius Pharmaceuticals, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry, with SIC code 2834.
What is the address of Salarius Pharmaceuticals' principal executive offices?
The principal executive offices are located at 2450 Holcombe Blvd. Suite X, Houston, TX 77021.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 21, 2025 regarding Salarius Pharmaceuticals, Inc. (DCOY).